{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:46:40Z","timestamp":1785862000713,"version":"3.56.0"},"reference-count":66,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>Following the publication of several landmark clinical trials such as dapagliflozin in patients with heart failure and reduced ejection fraction, dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction heart failure, and empagliflozin outcome trial in patients with chronic heart failure with preserved ejection fraction, sodium-glucose cotransport 2 inhibitors have been rapidly incorporated as a guideline-directed therapy in the treatment of heart failure. Moreover, their benefits appear to extend across the spectrum of left ventricular dysfunction which in some respects, can be seen as the holy grail of heart failure pharmacotherapy. Despite its plethora of proven cardioprotective benefits, the mechanisms by which it exerts these effects remain poorly understood, however, it is clear that these extend beyond that of promotion of glycosuria and natriuresis. Several hypotheses have emerged over the years including modification of cardiovascular risk profile via weight reduction, improved glucose homeostasis, blood pressure control, and natriuretic effect; however, these mechanisms do not fully explain the potent effects of the drug demonstrated in large-scale randomized trials. Other mechanisms may be at play, specifically the down-regulation of inflammatory pathways, improved myocardial sodium homeostasis, modulation of profibrotic pathways, and activation of nutrient deprivation signaling pathways promoting autophagic flux. This review seeks to summarize the cardioprotective benefits demonstrated in major clinical trials and provide a succinct review of the current theories of mechanisms of action, based on the most recent evidence derived from both clinical and laboratory data.<\/jats:p>","DOI":"10.1097\/crd.0000000000000637","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T09:01:29Z","timestamp":1704704489000},"page":"509-516","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects?"],"prefix":"10.1097","volume":"33","author":[{"given":"Patrick","family":"Savage","sequence":"first","affiliation":[{"name":"From the Royal Victoria Hospital Cardiology Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Dixon","sequence":"additional","affiliation":[{"name":"From the Royal Victoria Hospital Cardiology Department"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Grieve","sequence":"additional","affiliation":[{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University, Belfast, Northern Ireland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Watson","sequence":"additional","affiliation":[{"name":"Wellcome-Wolfson Institute for Experimental Medicine, Queen\u2019s University, Belfast, Northern Ireland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"R1-20251003","first-page":"ehad195","article-title":"Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"2023","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"R2-20251003","first-page":"175","article-title":"[From the discovery of phlorizin (a Belgian story) to SGLT2 inhibitors].","volume":"77","author":"Valdes-Socin","year":"2022","journal-title":"Rev Med Liege"},{"key":"R3-20251003","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors.","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"R4-20251003","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 inhibitors: physiology and pharmacology.","volume":"2","author":"Wright","year":"2021","journal-title":"Kidney360"},{"key":"R5-20251003","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"R6-20251003","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R7-20251003","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction.","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"key":"R8-20251003","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet (London, England)"},{"key":"R9-20251003","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control.","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"key":"R10-20251003","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"R11-20251003","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R12-20251003","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"R13-20251003","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"R14-20251003","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"R15-20251003","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial.","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"R16-20251003","doi-asserted-by":"crossref","first-page":"e227","DOI":"10.1093\/eurjpc\/zwab189","article-title":"Sodium glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis.","volume":"29","author":"Tsampasian","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"R17-20251003","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials.","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"R18-20251003","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER.","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"R19-20251003","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.3390\/ijms23073651","article-title":"An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors.","volume":"23","author":"Salvatore","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R20-20251003","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10741-020-10024-2","article-title":"Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors.","volume":"26","author":"Margonato","year":"2021","journal-title":"Heart Fail Rev"},{"key":"R21-20251003","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11897-021-00529-8","article-title":"SGLT2 inhibitors and their mode of action in heart failure-has the mystery been unravelled?","volume":"18","author":"Pabel","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"R22-20251003","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial.","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"R23-20251003","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"R24-20251003","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2019.01.109","article-title":"Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure - a multicenter propensity score matched analysis.","volume":"289","author":"T\u00e4ger","year":"2019","journal-title":"Int J Cardiol"},{"key":"R25-20251003","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13300-018-0385-5","article-title":"Empagliflozin induces transient diuresis without changing long-term overall fluid balance in Japanese patients with type 2 diabetes.","volume":"9","author":"Yasui","year":"2018","journal-title":"Diabetes Ther"},{"key":"R26-20251003","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in patients with heart failure, reduced ejection fraction, and volume overload: EMPEROR-reduced trial.","volume":"77","author":"Packer","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R27-20251003","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/dom.12572","article-title":"Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes.","volume":"17","author":"Chilton","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"R28-20251003","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"R29-20251003","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12933-018-0750-8","article-title":"Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.","volume":"17","author":"Aroor","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"R30-20251003","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/CIRCULATIONAHA.115.017545","article-title":"Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure.","volume":"133","author":"Bedi","year":"2016","journal-title":"Circulation"},{"key":"R31-20251003","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis.","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"R32-20251003","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","article-title":"Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients.","volume":"139","author":"Nielsen","year":"2019","journal-title":"Circulation"},{"key":"R33-20251003","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cmet.2016.07.018","article-title":"Empagliflozin\u2019s fuel hypothesis: not so soon.","volume":"24","author":"Lopaschuk","year":"2016","journal-title":"Cell Metab"},{"key":"R34-20251003","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/dom.13536","article-title":"Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: a hyperpolarized 13 C magnetic resonance spectroscopy study.","volume":"21","author":"Abdurrachim","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R35-20251003","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors.","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"R36-20251003","doi-asserted-by":"crossref","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats.","volume":"309","author":"O\u2019Neill","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"R37-20251003","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"R38-20251003","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction.","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R39-20251003","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics.","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R40-20251003","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis.","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"R41-20251003","first-page":"100725","article-title":"Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes.","volume":"33","author":"Benham","year":"2021","journal-title":"Int J Cardiol Heart Vasc"},{"key":"R42-20251003","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure.","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"R43-20251003","doi-asserted-by":"crossref","first-page":"e0215362","DOI":"10.1371\/journal.pone.0215362","article-title":"Effects of intensive blood pressure lowering on mortality and cardiovascular and renal outcomes in type 2 diabetic patients: a meta-analysis.","volume":"14","author":"Wang","year":"2019","journal-title":"PLoS One"},{"key":"R44-20251003","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurjhf\/hfn043","article-title":"Inflammation as a therapeutic target in heart failure? A scientific statement from the translational research committee of the heart failure association of the European society of cardiology.","volume":"11","author":"Heymans","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"R45-20251003","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation.","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovasc Res"},{"key":"R46-20251003","doi-asserted-by":"crossref","first-page":"108368","DOI":"10.1016\/j.diabres.2020.108368","article-title":"A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress.","volume":"168","author":"Bray","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"R47-20251003","doi-asserted-by":"crossref","first-page":"5593589","DOI":"10.1155\/2021\/5593589","article-title":"Influence of SGLT2 inhibitor treatment on urine antioxidant status in type 2 diabetic patients: a pilot study.","volume":"2021","author":"Nabrdalik-Le\u015bniak","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"R48-20251003","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders.","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"R49-20251003","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism"},{"key":"R50-20251003","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study.","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Heart Fail"},{"key":"R51-20251003","doi-asserted-by":"crossref","first-page":"39884","DOI":"10.1038\/srep39884","article-title":"Soluble uric acid activates the NLRP3 inflammasome.","volume":"7","author":"Braga","year":"2017","journal-title":"Sci Rep"},{"key":"R52-20251003","doi-asserted-by":"crossref","first-page":"e006277","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure.","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ Heart Fail"},{"key":"R53-20251003","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 Inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes Further augmentation of the effects with saxagliptin, a DPP4 inhibitor.","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"R54-20251003","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"R55-20251003","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/iub.1323","article-title":"The Na(+)\/H(+) exchanger and pH regulation in the heart.","volume":"66","author":"Odunewu-Aderibigbe","year":"2014","journal-title":"IUBMB Life"},{"key":"R56-20251003","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation.","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"R57-20251003","doi-asserted-by":"crossref","first-page":"112515","DOI":"10.1016\/j.biopha.2021.112515","article-title":"Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na+]c\/ROS-pathway in human endothelial cells.","volume":"146","author":"Uthman","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"R58-20251003","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.3390\/ijms22157976","article-title":"Cardioprotection by SGLT2 inhibitors\u2014does it all come down to Na+?","volume":"22","author":"Trum","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R59-20251003","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10557-021-07311-x","article-title":"Empagliflozin ameliorates ouabain-induced Na+ and Ca2+ dysregulations in ventricular myocytes in an Na+-dependent manner.","volume":"37","author":"Peng","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"R60-20251003","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radic Biol Med"},{"key":"R61-20251003","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart.","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"R62-20251003","first-page":"543","article-title":"Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results.","volume":"36","author":"Kang","year":"2020","journal-title":"Can J Cardiol"},{"key":"R63-20251003","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial.","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"R64-20251003","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol"},{"key":"R65-20251003","doi-asserted-by":"crossref","first-page":"107492","DOI":"10.1016\/j.intimp.2021.107492","article-title":"The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway.","volume":"94","author":"Meng","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R66-20251003","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet (London, England)"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:46:13Z","timestamp":1785858373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000000637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000637","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]}}}